RESUMEN
BACKGROUND: De-escalation therapy omitting anthracycline has been generally adopted for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. We investigated whether anthracycline can be omitted in HER2-positive early breast cancer patients receiving neoadjuvant taxane plus trastuzumab with clinical response. METHODS: HER2-positive primary breast cancer patients treated using NAC containing trastuzumab were enrolled between September 2006 and July 2018 at Osaka Breast Clinic. The primary outcome was disease-free survival (DFS). The secondary outcome was overall survival (OS). We investigated survival with or without ï¬uorouracil, epirubicin, and cyclophosphamide (FEC) using the log-rank test and propensity score matching (PSM). RESULTS: In total, 142 patients were retrospectively included and median follow-up was 61 months. There was no significant difference in DFS (p = 0.93) and OS (p = 0.46) between the FEC-omitted group and the FEC-added group. The 5-year DFS was 91% and 88% and OS was 100% and 100%, respectively. After PSM, the FEC-omitted group and the FEC-added group had no significant differences in DFS (p = 0.459) and there were no death events in either group. The 5-year DFS was 90% and 88% and OS was 100% and 100%, respectively. CONCLUSIONS: Using PSM, the 5-year DFS of HER2-positive early breast cancer was not different with or without anthracycline. Response-guided omission of anthracycline may be an option for HER2-positive early breast cancer patients receiving neoadjuvant taxane and trastuzumab with good response in order to avoid overtreatment.
Asunto(s)
Neoplasias de la Mama , Terapia Neoadyuvante , Antraciclinas/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Quimioterapia Adyuvante , Ciclofosfamida , Epirrubicina , Femenino , Fluorouracilo , Estudios de Seguimiento , Humanos , Terapia Neoadyuvante/efectos adversos , Pronóstico , Puntaje de Propensión , Receptor ErbB-2/metabolismo , Estudios Retrospectivos , Taxoides/uso terapéutico , TrastuzumabRESUMEN
Eosinophilic pustular folliculitis (EPF) is a non-infectious inflammatory dermatosis of unknown etiology that principally affects the hair follicles. There are three variants of EPF: (i) classic EPF; (ii) immunosuppression-associated EPF, which is subdivided into HIV-associated (IS/HIV) and non-HIV-associated (IS/non-HIV); and (iii) infancy-associated EPF. Oral indomethacin is efficacious, especially for classic EPF. No comprehensive information on the efficacies of other medical management regimens is currently available. In this study, we surveyed regimens for EPF that were described in articles published between 1965 and 2013. In total, there were 1171 regimens; 874, 137, 45 and 115 of which were applied to classic, IS/HIV, IS/non-HIV and infancy-associated EPF, respectively. Classic EPF was preferentially treated with oral indomethacin with efficacy of 84% whereas topical steroids were preferred for IS/HIV, IS/non-HIV and infancy-associated EPF with efficacy of 47%, 73% and 82%, respectively. Other regimens such as oral Sairei-to (a Chinese-Japanese herbal medicine), diaminodiphenyl sulfone, cyclosporin and topical tacrolimus were effective for indomethacin-resistant cases. Although the preclusion of direct comparison among cases was one limitation, this study provides a dataset that is applicable to the construction of therapeutic algorithms for EPF.
Asunto(s)
Eosinofilia/tratamiento farmacológico , Foliculitis/tratamiento farmacológico , Enfermedades Cutáneas Vesiculoampollosas/tratamiento farmacológico , Adulto , Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Eosinofilia/clasificación , Eosinofilia/etiología , Foliculitis/clasificación , Foliculitis/etiología , Infecciones por VIH/complicaciones , Humanos , Terapia de Inmunosupresión/efectos adversos , Indometacina/uso terapéutico , Lactante , Fitoterapia , Remisión Espontánea , Enfermedades Cutáneas Vesiculoampollosas/clasificación , Enfermedades Cutáneas Vesiculoampollosas/etiología , Esteroides/uso terapéutico , Resultado del TratamientoRESUMEN
Candida albicans malate dehydrogenase (Mdh1p) has been screened by previous proteome studies as a candidate for a vaccine against candidiasis. In this study, recombinant Mdh1 protein with a His-tag was produced in Escherichia coli and evaluated as an immunogenic protein against candidiasis. Mdh1p was administrated to mice by two methods subcutaneous injection and intranasal administration before challenging them with a lethal dose of C. albicans. After vaccination of Mdh1p, antibody responses were observed. To evaluate the vaccination effect of Mdh1p, survival tests were performed after 35 d. Although all control mice died within 24 d or 25 d, 100% and 80% of mice survived with subcutaneous and intranasal administration, respectively. Therefore, our results indicate that, among C. albicans antigens examined thus far, Mdh1p is currently the most effective antigen for use as a vaccine for C. albicans.
Asunto(s)
Candida albicans/enzimología , Candidiasis/prevención & control , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/inmunología , Malato Deshidrogenasa/inmunología , Animales , Anticuerpos Antifúngicos/inmunología , Candida albicans/genética , Candida albicans/inmunología , Candidiasis/inmunología , Candidiasis/microbiología , Evaluación Preclínica de Medicamentos , Femenino , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/genética , Vacunas Fúngicas/administración & dosificación , Vacunas Fúngicas/genética , Humanos , Malato Deshidrogenasa/administración & dosificación , Malato Deshidrogenasa/genética , Ratones , Ratones Endogámicos C57BL , VacunaciónRESUMEN
Paired-associative stimulation (PAS), combining electrical median nerve stimulation with transcranial magnetic stimulation (TMS) with a variable delay, causes long-term potentiation or depression (LTP/LTD)-like cortical plasticity. In the present study, we examined how PAS over the motor cortex affected a distant site, the somatosensory cortex. Furthermore, the influences of PAS on high-frequency oscillations (HFOs) were investigated to clarify the origin of HFOs. Interstimulus intervals between median nerve stimulation and TMS were 25 ms (PAS(25)) and 10 ms (PAS(10)). PAS was performed over the motor and somatosensory cortices. SEPs following median nerve stimulation were recorded before and after PAS. HFOs were isolated by 400-800 Hz band-pass filtering. PAS(25) over the motor cortex increased the N20-P25 and P25-N33 amplitudes and the HFOs significantly. The enhancement of the P25-N33 amplitude and the late HFOs lasted more than 60 min. After PAS(10) over the motor cortex, the N20-P25 and P25-N33 amplitudes decreased for 40 min, and the HFOs decreased for 60 min. Frontal SEPs were not affected after PAS over the motor cortex. PAS(25/10) over the somatosensory cortex did not affect SEPs and HFOs. PAS(25/10) over the motor cortex caused the LTP/LTD-like phenomena in a distant site, the somatosensory cortex. The PAS paradigms over the motor cortex can modify both the neural generators of SEPs and HFOs. HFOs may reflect the activation of GABAergic inhibitory interneurons regulating pyramidal neurons in the somatosensory cortex.
Asunto(s)
Relojes Biológicos/fisiología , Potenciales Evocados Somatosensoriales/fisiología , Corteza Motora/fisiología , Corteza Somatosensorial/fisiología , Adulto , Vías Aferentes/fisiología , Estimulación Eléctrica , Femenino , Humanos , Interneuronas/fisiología , Masculino , Nervio Mediano/fisiología , Corteza Motora/anatomía & histología , Inhibición Neural/fisiología , Vías Nerviosas/anatomía & histología , Vías Nerviosas/fisiología , Plasticidad Neuronal/fisiología , Células Piramidales/fisiología , Tiempo de Reacción/fisiología , Corteza Somatosensorial/anatomía & histología , Factores de Tiempo , Estimulación Magnética Transcraneal , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Excessive daytime sleepiness has been widely accepted as a common problem not only in Parkinson's disease (PD) but also in other related disorders. Lowered excretion of orexin A (hypocretin 1) into the cerebrospinal fluid (CSF) is known to play a pathological role in narcolepsy and secondary hypersomnia due to hypothalamic dysfunction. Although the levels of CSF orexin in PD have been previously examined, the results have been controversial, and no systematic investigation of CSF orexin excretion has been conducted on PD related disorders. In this study, orexin was measured in CSF collected by lumbar puncture in 62 patients with PD, 13 patients with dementia with Lewy bodies (DLB), 16 patients with progressive supranuclear palsy (PSP), and 7 patients with corticobasal degeneration (CBD). Levels of CSF orexin (mean+/-SD pg/ml) were 302+/-38 in PD, 297+/-48 in DLB, 258+/-37 in PSP, 246+/-90 in CBD. The occurrence of low orexin levels (Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/líquido cefalorraquídeo
, Enfermedad por Cuerpos de Lewy/líquido cefalorraquídeo
, Neuropéptidos/líquido cefalorraquídeo
, Enfermedad de Parkinson/líquido cefalorraquídeo
, Esclerodermia Difusa/líquido cefalorraquídeo
, Trastornos del Sueño-Vigilia/líquido cefalorraquídeo
, Anciano
, Anciano de 80 o más Años
, Biomarcadores/análisis
, Biomarcadores/líquido cefalorraquídeo
, Proteínas del Líquido Cefalorraquídeo/análisis
, Proteínas del Líquido Cefalorraquídeo/metabolismo
, Progresión de la Enfermedad
, Regulación hacia Abajo/fisiología
, Femenino
, Humanos
, Hipotálamo/metabolismo
, Hipotálamo/fisiopatología
, Enfermedad por Cuerpos de Lewy/diagnóstico
, Enfermedad por Cuerpos de Lewy/fisiopatología
, Masculino
, Persona de Mediana Edad
, Orexinas
, Enfermedad de Parkinson/diagnóstico
, Enfermedad de Parkinson/fisiopatología
, Valor Predictivo de las Pruebas
, Esclerodermia Difusa/diagnóstico
, Esclerodermia Difusa/fisiopatología
, Trastornos del Sueño-Vigilia/etiología
, Trastornos del Sueño-Vigilia/fisiopatología
, Punción Espinal